Nadia Solovieff, Ph.D.
Affiliations: | 2011 | Boston University, Boston, MA, United States |
Area:
Statistics, Epidemiology, GeneticsGoogle:
"Nadia Solovieff"Parents
Sign in to add mentor| Paola Sebastiani | grad student | 2011 | Boston University | |
| (Clustering by genetic ancestry using genome-wide single nucleotide polymorphisms and incorporating genetic ancestry into genetic risk prediction models.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Andre F, Su F, Solovieff N, et al. (2020) Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials. Journal of Clinical Oncology. 38: 1009-1009 |
| Neven P, Petrakova K, Bianchi GV, et al. (2019) Abstract PD2-05: Biomarker analysis by baseline circulating tumor DNA alterations in the MONALEESA-3 study Cancer Research. 79 |
| Yap Y, Su F, Solovieff N, et al. (2019) Abstract CT143: Baseline circulating tumor DNA (ctDNA) analysis in Asian women with HR+/HER2- advanced breast cancer (ABC) receiving ribociclib + endocrine therapy in the Phase Ib MONALEESASIA trial Cancer Research. 79 |
| Bardia A, Su F, Solovieff N, et al. (2019) Abstract CT141: Genetic landscape of premenopausal HR+/HER2- advanced breast cancer (ABC) based on comprehensive circulating tumor DNA analysis and association with clinical outcomes in the Phase III MONALEESA-7 trial Cancer Research. 79 |
| Solovieff N, Su F, Leary R, et al. (2019) Abstract A031: Association of tumor DNA in circulation with clinical characteristics and treatment response in HR+/HER2− advanced breast cancer Molecular Cancer Therapeutics. 18 |
| Hortobagyi G, Stemmer S, Campone M, et al. (2018) Abstract PD4-06: First-line ribociclib + letrozole in hormone receptor-positive, HER2-negative advanced breast cancer: Efficacy by baseline circulating tumor DNA alterations in MONALEESA-2 Cancer Research. 78 |
| Solovieff N, Wang YA, Sankaran B, et al. (2018) Abstract A029: Biomarker analysis in HR+, HER2-, locally advanced, or metastatic breast cancer patients treated with buparlisib: results from BELLE-3 Molecular Cancer Therapeutics. 17 |
| Solovieff N, Singh AP, Bitter H, et al. (2015) Abstract A02: Biomarkers of drug response to buparlisib: Results of next-generation sequencing in a phase II trial of advanced endometrial carcinoma Molecular Cancer Therapeutics. 14 |
| Solovieff N, Hims M, Leary R, et al. (2015) Abstract LB-A05: Profiling cell free DNA in breast cancer and non-small cell lung cancer using broad NGS assessment Molecular Cancer Therapeutics. 14 |
| Guffanti G, Ashley-Koch AE, Roberts AL, et al. (2014) No association between RORA polymorphisms and PTSD in two independent samples. Molecular Psychiatry. 19: 1056-7 |